ArQule strengthens management lineup with Citibank and Ariad alumni

25 May 2018

ArQule (Nasdaq: ARQL) announced on Friday that it was strengthening its management team with the addition of two new senior vice presidents, former Citibank banking director Marc Schegerin and Shirish Hirani, a longstanding VP of drug development at Ariad Pharmaceuticals.

Paolo Pucci, ArQule's chief executive, said: "Marc’s medical background, paired with his experience in healthcare and investment banking, and Shirish’s expertise in both drug development and operations will be essential as ArQule continues to advance its precision medicine programs in both oncology and rare diseases."

In addition to his role at Citibank, Dr Schengerin has lectured at Harvard University and worked in senior strategy roles with Biogen (Nasdaq: BIIB) and Sage Therapeutics (Nasdaq: SAGE). He has also served as vice president at Bank of America Merrill Lynch as well as an associate at Goldman Sachs.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK